Leah Kuntz

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Check out our pipeline updates from August!

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Meta faces an $18B teen-safety settlement, adding time limits, night and school modes, parental controls, and tighter age checks across Instagram and Facebook.

FDA clears a simple pTau217 blood test that helps clinicians rule in or out Alzheimer’s amyloid earlier, expanding access beyond PET/CSF.

Clearmind patents MDMA plus PEA combo aiming to boost PTSD, anxiety and eating-disorder therapy as FDA issues new psychedelic trial guidance.

PleoPharma secures $6.5M NIDA grant to advance phase 3 PP-01 trial, aiming to ease cannabis withdrawal and address untreated cannabis use disorder.

FDA signals clear IND path for PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder.

FDA clears a Parkinson disease wearable and fast-tracks ecopipam for pediatric Tourette syndrome, showing advances in neuropsychiatric care.

Recognize postpartum psychosis fast: early signs, key risk factors, OCD vs delusions, and evidence-based lithium-centered treatment for urgent care.

Explore suicide prevention in psychiatry—risk assessment, treatment challenges, and emerging research. Submit your case or CME for August 2026.

Fitbit and Google Health app data feed Amae clinicians real-time sleep, physical activity, and heart rate variability signals to spot relapse early in severe mental illness.

Clancy trial spotlights postpartum psychosis: how to recognize warning signs, emergency treatment options, and why stigma and DSM gaps hinder care.

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.

Check out the pipeline updates from July!

New analysis shows COMP360 psilocybin sessions for PTSD stay mostly silent, with nondirective support boosting safety and autonomy.

Phase 2 ZEPHYR finds oral betovumeline combo reduces PANSS and improves cognition in acute schizophrenia, with generally mild side effects.

ASCP updates spotlight ketamine safety guardrails, at‑home agitation therapy, psilocybin phase 3 momentum, and biomarker-driven precision psychiatry.

Top 2026 psychiatry conference takeaways: mixed-feature bipolar care, GLP-1 addiction trials, schizophrenia adherence, TD gaps, AI prodrome screening.

New data show APOE4 worsens early sleep disruption in Alzheimer models; CN-105 and zolpidem restore deep sleep and may slow amyloid buildup.

FDA grants Fast Track to Acadia’s remlifanserin for Alzheimer disease psychosis, targeting hallucinations and delusions as RADIANT trial advances toward 2026 data.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.

Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.